1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 18, 1998
-------------------------
GISH BIOMEDICAL, INC.
(Exact name of Registrant as specified in its charter)
California 0-10728 95-3046028
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No)
2681 Kelvin Avenue, Irvine, California 92715
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (949) 756-5485
----------------------
Not Applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Page 1 of 5
Exhibit Index on Page 4
2
ITEM 5. OTHER EVENTS
On November 18, 1998, the Gish Biomedical, Inc. (the "Company") held its
annual meeting of shareholders at the principal offices of the Company in
Irvine, California.
At the annual meeting, a shareholder which had recently purchased a
substantial block of the Company's Common Stock requested the exercise of its
right to cumulative voting under California law in the election for directors.
The Company complied with the shareholder's request. Such shareholder also
nominated to the Company's Board of Directors Mr. Howard F.
Bovers.
The results of the election were that five of the six nominees to the
Company's Board of Directors presented in the Company's proxy statement dated
October 12, 1998 were elected to serve one year terms, all of whom were
incumbent directors of the Company. The re-elected directors are Jack W. Brown,
Ray R. Coulter, Richard W. Dutrisac, James B. Glavin and John S. Hagestad.
Additionally, Howard F. Bovers was elected to a one year term on the
Company's Board of Directors, principally as a result of votes cast by proxies
held by the party which had recently acquired the shares discussed above.
ITEM 7. EXHIBITS
EXHIBIT NO. DESCRIPTION
99.1 Press Release Dated November 24, 1998
2 of 5
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
GISH BIOMEDICAL, INC.
Date: November 25, 1998 By: /s/ JEANNE M. MILLER
-------------------------------
Jeanne M. Miller
Chief Financial Officer
3 of 5
4
EXHIBIT INDEX
SEQUENTIAL
EXHIBIT NO. DESCRIPTION PAGE NO.
- ----------- ----------- --------
99.1 Press Release dated November 24, 1998 5
4 of 5